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ttp://dx.doi.org/10.1016/j.ajpath.2013.01.009There has been an explosion of articles on epithelial-mesenchymal transition and other modes of
cellular reprogramming that inﬂuence the tumor microenvironment. Many controversies exist and
remain to be resolved. The interest of the pathologists in the molecular and functional parallels
between wound healing and the developing tumor stroma has its earliest origin in the writings of
Rudolph Virchow in the 19th century. Since then, most of the focus has been primarily on the dynamics
of the extracellular matrix; however, new interest has been redirected toward deciphering and under-
standing the enigmatic, yet elegant, plasticity of the cellular components of the proliferating epithelia
and stroma and how they are reciprocally inﬂuenced. Citing several examples from breast cancer
research, we will trace how these perspectives have unfolded in the pages of The American Journal of
Pathology and other investigative journals during the past century, their impact, and where the ﬁeld is
headed. (Am J Pathol 2013, 182: 1055e1064; http://dx.doi.org/10.1016/j.ajpath.2013.01.009)Supported by the intramural program of the National Cancer Institutes
and the National Institute on Minority Health and Health Disparities.In 1858, Rudolph Virchow ﬁrst proposed his irritation theory
for cancer.1,2 This concept was based on the observation that
neoplastic lesions often develop at sites of chronic irritation.
Virchow concluded that irritation of any type, including
mechanical, chemical, or thermal, was “the essential factor of
neoplastic tissue proliferation.”2,pp 511 Through an astute
synthesis of these general observations with the microscopic
ﬁnding that foci of irritation or abnormal excitation were
invariably associated with a reactive process characterized by
inﬁltration of inﬂammatory cells, Virchow later proposed his
more celebrated concept that there is a causal link between
inﬂammation and cancer.1,2 More than a century later,
Dvorak colorfully coined the phrase that cancer was “a
wound that does not heal,”3 implying that the cellular and
biochemical processes associated with wound healing are
similar to those involved in the growth and development of
tumor stroma. However, one of the earliest written recogni-
tions of this similarity appeared, in 1924, in the Journal of
Medical Research, the immediate predecessor of The
American Journal of Pathology, in an article submitted by
Montrose T. Burrows, entitled “Studies on Wound Healing: I
‘First Intention’ Healing of Open Wounds and the Nature of
the Growth Stimulus in the Wound and Cancer.” Although,
unlike Virchow, Burrows dismissed the possible signiﬁcancemerican Society for Investigative Pathology.of the role played by the inﬁltrating lymphocytes, he did
recognize the critical importance of the relationship between
the different ﬁxed cells of epithelium and connective tissue in
the generation of growth stimuli during the wound response.
This led him to suggest that “cancer may be nothing more
than a break in the balance” between these two populations.
This notion was later reiterated by Haddow4 in 1972.
Notwithstanding its noted resemblance to cancer growth and
invasion, the regenerative processes associated with wound
healing have been a favorite topic of investigation by
experimental pathologists for more than a century.5,6 A
consistent and recurrent theme has been that the healing
wound response can be characterized by three important
factors: epithelial movements, cell proliferation, and
contraction (or remodeling).5,7 It is generally accepted that
wound healing is a sequential process that can be separated
into three overlapping phases in which the appearance,
growth, and differentiation of speciﬁc constituents have
many similarities to developing tumor stroma. They include
the following: i) inﬂammation, ii) proliferation, and iii)
maturation. These processes differ in cancer and wound
Byun and Gardnerhealing at the level of regulation, where there is lost control of
multiple cellular, molecular, and biochemical processes that
characterize each step.The Phases of Wound Healing and Their
Similarity to Tumor Stroma Growth
The word inﬂammation is derived from the Latin inﬂam-
matio, which means to ignite or set a ﬁre. Although the role of
nucleated cellular components of inﬂammation is the focus of
modern cell biology, the most immediate and pronounced
components of inﬂammation are the leakage of serum
components, red blood cells, and platelets into the extracel-
lular space of the connective tissue to initiate clot formation.
Precipitated by disrupted vasculature integrity by either
physical or biological injury, spilled plasma components are
exposed to numerous thrombogenic elements in the extra-
vascular space, thus initiating the clotting cascade via
thrombin-cleaved conversion of leaked ﬁbrinogen to ﬁbrin,
through the action of tissue factor, thromboplastin, combined
with factor VII.8,9 The cleaved ﬁbrin monomers then poly-
merize to form a ﬁbrin gel that is stabilized by the cross-
linking activity of factor XIIIa.9 In combination with other
components leaked from the vasculature, such as ﬁbronectin,
the ﬁbrin gel forms a provisional matrix along which the
other ﬁxed cellular components of the epithelium and
connective tissue can begin to wander.9e11 At the same time,
leaked platelets become activated by interaction with extra-
cellular matrix (ECM) components in the extravascular
space, including collagen and von Willebrand’s factor, to
initiate the primary hemostatic process. The platelets degra-
nulate, liberating a variety of factors, including ﬁbrinogen,
ﬁbronectin, platelet-derived growth factor (PDGF), trans-
forming growth factor b (TGF-b), histamine, epinephrine,
and serotonin, that enhance the clotting cascade and, in
combination with components of complement activation,
attract a variety of cellular components.9,12 In addition to
amplifying platelet activation and aggregation to form the
primary hemostatic plug, these secreted factors serve to
recruit a succession of cell types, including neutrophils, fol-
lowed by mast cells, monocytes, and ﬁbroblasts, into the
wound area.3,9,13 In normal wound healing, hemostasis rea-
ches completion, the extravasation subsides, and the
inﬂammatory phase resolves with the replacement of the
highly active provisional ﬁbrin/ﬁbronectin matrix with
collagen. However, in tumor stroma, the lost integrity of the
vasculature is not the result of mechanical, chemical, or
biological injury; rather, it is the result of dramatic increases
in the permeability of the vasculature due to elevated levels of
vascular endothelial growth factor (VEGF), alias vascular
permeability factor, secreted by the tumor cells.3,14,15 The
persistent ﬁbrin and ﬁbronectin deposition provides a sus-
tained impetus that drives continuous recruitment, prolifer-
ation, and developmental differentiation in both the stromal
and epithelial compartments.3,4,7,131056The proliferation phase of wound healing is marked by
a robust increase in new tissue and expansion of the cellular
mass. Under the inﬂuence of VEGF, new vessel formation
occurs by increasing proliferation and migration of endo-
thelial cells. PDGF induces the migration and proliferation
of both ﬁbroblasts and pericytes, the subendothelial cells
that maintain capillary integrity.3,4,7,13 Entering monocytes
begin to proliferate and differentiate into macrophages.
Through this process, what is known as granulation tissue,
the newly revascularized matrix of the wound forms, fol-
lowed by hypertrophy and increased migration of the
neighboring epithelium. Thus, the proliferation phase can be
characterized by a massive and extensive phenotypic
reprogramming of nearly all of the cellular components. In
each case, this reprogramming is altered and/or exaggerated
in the tumor stroma, changes that ultimately promote tumor
progression.3,4,7,13 We will examine the role and function of
some of the major components.Tumor-Associated Macrophages
Monocytes that are recruited to the wound quickly differen-
tiate into macrophages and are the most highly represented cell
type in the healing wound and tumor stroma.16,17 In the case of
breast cancer, tumor-associated macrophages (TAMs) have
been known to compose as much as 50% of the tumor mass.18
This cellular system represents one of the most plastic
components in both wound and tumor stroma, with a wide
range of phenotypes whose programs are highly dependent
and responsive to the microenvironment.16,17,19e23 Although
there is signiﬁcant disagreement about the different functional
macrophage phenotypes, it is generally accepted that macro-
phages can be polarized into two generally distinct pheno-
types.16,17,19 The macrophages frequently found in early
healing wounds are the M1 phenotype. M1 macrophages are
typically perceived as having tissue-destructive attributes that
are polarized under the control of cytokines secreted by type 1
helper T-cell lymphocytes (eg, interferon-g and tumor necrosis
factor-a), in which they express high levels of major histo-
compatibility complex class II receptors and secrete IL-12 and
IL-23 to ﬁll a major role in combating infection by virus and
other intracellular pathogens.16,17,19,21,24 Major transcriptional
programs associatedwithM1macrophages are driven by Stat1
with broadened ampliﬁcation through NF-kB networks.16,19,25
M2 macrophages represented a second alternatively reprog-
rammed class of activated cells that often have attributes that
are considered wound resolving and increase in prominence at
the later stages of wound healing.19,21,24,25 This polarized
phenotype is generally directed by cytokine signaling from
type 2 helper T-cell lymphocytes (IL-4 and IL-13). M2
macrophages typically show low expression of major histo-
compatibility complex class II complexes and characteristi-
cally express stabilin-1 and arginase-1, which may function in
building components of the ECM.16,19,25 The transcription
networks that predominate in M2 macrophages are Stat3 andajp.amjpathol.org - The American Journal of Pathology
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peroxisome proliferator-activated receptor-g, and C/EBP-b.
They secrete IL-17, high levels of IL-10, and low levels of
IL-12 and, thus, are thought to have a role in dampening
the immune response.23 Notably, M2 macrophages also
commonly secrete VEGF, TGF-b, EGF, prostaglandin E2,
and matrix metalloproteinase (MMP)-9 and are, therefore,
thought to play a signiﬁcant role in angiogenesis and ECM
remodeling in wounds and the tumor.19,25 As previously
mentioned, the distinctions between M1 and M2 are blurred
and there is ample evidence suggesting a signiﬁcant role for
phenotype switching in response to tissue and tumor
microenvironment.21 Tumor-secreted chemokine ligand 2
and monocyte colony-stimulating factor play a prominent
role in the accumulation of TAMs, in which theM2 phenotype
is thought to play a signiﬁcant role in promoting tumor inva-
sion and metastasis.19,21,24 Although there are conﬂicting
reports, several studies have shown that the presence and
amount of TAMs, particularly of the M2-like phenotype, is
a poor prognostic factor in carcinoma of the breast and many
other types of cancer.24,26 In fact, recent studies suggest a role
for TAMs in the racial/ethnic differences in breast cancer
survival.27,28 Moreover, the interaction between stromal
macrophages and tumor is highly responsive to changes in the
tumor microenvironment, and can respond to alterations in the
tumor stroma secondary to events as diverse as cytotoxic
chemotherapy, hormonal treatment, and local tissue events
that induce hypoxia.19,21,22,25,29The Role of Myoﬁbroblasts in Tumor Stroma
The most commonly recognized ﬁxed or tissue-resident
components of connective tissue are loosely referred to as
ﬁbroblasts. However, the ﬁbroblast is, by far, one of the
most phenotypically dynamic and enigmatic cellular
components of the wound healing and tumor stroma.30e34
The origin of reprogrammed ﬁbroblasts and ﬁbroblast-
derived cells is diverse.30,31 After inﬂammatory injury,
ﬁbroblasts are activated to migrate and proliferate in the
wound area through interaction with the provisional ﬁbrin
matrix, where they begin to proliferate and initiate a differ-
entiation program that drives the acquisition of secretory
and contractile properties of myoﬁbroblasts. This is marked
by increased expression of a-smooth muscle actin and
increased synthesis of collagen types I and III33,34; however,
the spectrum of gene expression in myoﬁbroblasts is highly
diverse and speciﬁc to anatomical locations.35 The prolif-
eration and reprogramming of ﬁbroblast to myoﬁbroblast is
driven by the ED-A splice variant of ﬁbronectin; TGF-b
secreted by platelets, macrophages, and normal and malig-
nant epithelia; and changes in the mechanoregulatory
properties of ECM stiffness.36 In addition to inﬂuencing
TGF-b availability, the mechanical properties of the ECM
also have signiﬁcant inﬂuence on myoﬁbroblast differenti-
ation through the regulation of focal adhesion and activationThe American Journal of Pathology - ajp.amjpathol.orgof the focal adhesion kinase signaling. Thus, ECM stiffness
drives myoﬁbroblast differentiation by a variety of mecha-
nisms. Developing myoﬁbroblasts have a twofold higher
contractile activity than normal ﬁbroblasts; throughout, the
wound process begins to assume the mechanical load
through growth and maturation of its adherence with the
ECM via focal adhesion complexes linked to cytoskeleton
to transduce signals that further promote the myoﬁbroblast
transcriptional program.32,34,36 In normal healing, once the
ECM has taken over the normal mechanical load, the
myoﬁbroblast undergoes massive apoptosis.37 However, the
constant remodeling of the ECM of the tumor stroma,
driven in part by the continuous TGF-b, ﬁbroblast growth
factor, and PDGF stimulation and matrix reshaping by
MMPs secreted by TAMs, platelets, and tumor epithelia,
provides a milieu in which the myoﬁbroblast population
persists.31,33,34,38 Recently, another novel mode of myoﬁ-
broblast activation has been identiﬁed, in which secreted
exosome components, derived from tumor cells, drive
myoﬁbroblast reprogramming under the inﬂuenced TGF-b
signaling.39e41 Myoﬁbroblasts are recruited from a diverse
array of precursors, and each source plays a signiﬁcant and
distinct role in driving tissue- and organ-speciﬁc ﬁbrotic
pathological conditions, ranging from the formation of
reactive tumor stroma to hepatic, pulmonary, and renal
ﬁbrosis.31,33,34,42,43 In addition to tissue-resident ﬁbroblasts,
these sources include ﬁbrocytes (bone marrowederived
ﬁbroblast precursors distinguished by the presence of
multiple hematopoietic surface markers44,45), local and bone
marrowederived mesenchymal stem cells,46 pericytes (the
support layer of small vessels),47e51 smooth muscle cells,52
endothelial cells,43,53,54 and normal and malignant epithelial
cells.31,34,43 Once activated, myoﬁbroblast cells secrete
a constellation of substances that promote tumor growth,
invasion, and metastasis, including MMPs (MMP-1, MMP-2,
MMP-3, MMP-9, MMP-13, and MMP-1455), tissue
inhibitor of metalloproteinases, IL-1, IL-6, IL-8, TGF-b,
EGF, basic ﬁbroblast growth factor, and hepatocyte growth
factor, in addition to collagens I and III and ﬁbro-
nectin.31,34,36 During the initial stages after myoﬁbroblast
activation, collagen III is the main secreted collagen that
provides a substrate for continued migration and support for
developing granulation tissue formation and angiogenesis.
Recently, myoﬁbroblast activation has been divided into
two phases, one characterized by reprogrammed acquisition
of contractile cytoskeletal features and referred to as pro-
tomyoﬁbroblast.31,34,36 Mechanical stress and TGF-b drive
further reprogramming of protomyoﬁbroblasts to express a-
smooth muscle actin in the stress ﬁbers and contractile
apparatus and, thus, become true contractile myoﬁbro-
blasts.31 This activation is facilitated by broad roles played
by transmembrane integrin in the activation of latent TGF-
b associated with the ECM.56,57 Myoﬁbroblasts also secrete
high levels of glycosylated proteins, including glycosami-
noglycan and proteoglycans.33,34,36,58 One of these
components, hyaluronan, acts in a feedback mechanism to1057
Byun and Gardnerenhance TGF-beinduced myoﬁbroblast activation.59e61
Interestingly, recent studies have found that a dominant pop-
ulation of reprogrammed myoﬁbroblasts shows decreased
expression of caveolin-1 linked to a functional inactivation
of Rb and consequent up-regulated expression of Rb/E2F
controlled gene networks.62,63 These caveolin-deﬁcient
myoﬁbroblasts were found to produce high levels of hepa-
tocyte growth factor and TGF-b.62,64
Endothelial Cell and Pericyte Reprogramming
Major components of the formation of granulation tissue
during wound healing and the tumor angiogenesis are the
endothelial cells and pericytes. For comprehensive reviews,
we refer to several outstanding articles on angiogenesis
published in The American Journal of Pathology and else-
where.7,14,65 However, as previously stated, the increased
proliferation of both endothelial cells and pericytes, asso-
ciated with wound healing and reactive tumor stroma, is
subject to reprogramming at many different levels. Endo-
thelial transitions to myoﬁbroblast-like phenotypes have
been observed in several tissues and are associated with loss
of cellular adhesion molecules in response to TGF-b and the
acquisition of expression at a-smooth muscle actin and
collagen type I, sometimes in association with tumors at the
invasive front.43,53,54,66,67 Despite the known role of peri-
cytes in angiogenesis,68,69 the reprogramming of pericytes
to acquire ﬁbroblast features is only beginning to be
explored. It is best understood in studies of renal
ﬁbrosis47,48,70,71 and, most notably, in liver ﬁbrosis, in
which the hepatic stellate cells, the pericytes of liver, are
reprogrammed to myoﬁbroblasts primarily through the
action of TGF-b secreted from the Kupffer cells (resident
macrophages) and platelets.50
Epithelial Reprogramming in Wound Healing
and the Tumor Stroma
The most irretrievable event that leads to a terminal prog-
nosis in patients with cancer is the progression to stage IV
disease, the presence of distant metastasis.72e74 The
reprogramming of malignant cells through epithelial-
mesenchymal transition represents the ﬁrst step in the
metastatic cascade. In this ﬁrst step, a cancer cell must
acquire the ability to invade the surrounding tissue. After
invasion and breach of the basement membrane, it must gain
access to the circulation through intravasation of blood or
lymphatic vessels. Once in the circulation, the tumor cell
must survive as a single cell until transported to distant
tissues, where it must exit the vasculature or extravasate into
the surrounding tissue to survive, proliferate, and reprogram
to reacquire epithelial characteristics so that it may mature
and colonize locally as a metastatic tumor.74 The reac-
quisition of mesenchymal features after metastasis is
referred to as mesenchymal-epithelial transition, a process1058that is often coupled with epithelial-mesenchymal transition
(EMT) during embryonic development and plays a critical
role in the development and seeding of metastatic dis-
ease.74e78 The reprogramming events during EMT are
highly contextual; thus, the form and extent of this process
are critically linked to the microenvironment.76,79,80 This
dynamic reprogramming is stimulated by a wide variety of
agents, including TGF-b, bone morphogenetic proteins,
Wnt signaling, ﬁbroblast growth factors, hepatocyte growth
factor, PDGF, Notch and Sonic Hedge Hog signaling,
VEGF, inﬂammation, hypoxia, obesity, oxidative stress,
and external agents (eg, smoking, UV irradiation, and
alcohol).76,81 EMT is a normal physiological process that
was ﬁrst described as a transdifferentiation event associated
with tissue and organ morphogenesis during embryonic
development.76,80,82 The primary features of EMT are a loss
of epithelial tethering to neighboring cells and the basement
membrane. This occurs in combination with a consequent
increase in the mesenchymal features, characterized by loss
of polarity, increased mobility and migration, and resistance
to anoikis.76,77,79,80 At the cellular level, these changes are
deﬁned by loss of various junctional complexes common to
epithelial cells, including desmosomes, adherens junctions,
tight junctions, and gap junctions. Accordingly, there is
a reciprocal increase in acquisition of mesenchymal
molecular features, including a switch from epithelial
keratin to increased production of the intermediate ﬁlaments
containing vimentin, the appearance of N-cadherin at the
membrane surface, and the secretion of ﬁbronectin and
MMPs capable of digesting the basement membrane.76,79,80
Integrins are a family of heterodimeric transmembrane
proteins, composed of a and b subunits, that play a vast role
in maintaining and regulating cellular attachments and
interactions with the ECM.83 There are 18 known a subunits
and 8 b subunits capable of forming 25 different cell
adhesion complexes, each speciﬁc for different components
of the ECM (eg, laminin, ﬁbronectin, and vitronectin), as
dictated by cell type, condition, and spatial orientation.83
The role of integrins in the wound healing response is
complex, with shifting repertoires of receptors that inﬂuence
cell typeespeciﬁc adhesion with, and migration through, the
continuously remodeled provisional matrix of the tumor
stroma.84,85 Thus, the integrin repertoire will likely reﬂect
different reprogrammed states within both the tumor cell
and the other cellular components of the tumor stroma at
different stages of invasion, intravasation, metastasis,
extravasation, and recolonization of distant tissues after
mesenchymal-epithelial transition. Just as cellular events
inside the cell can inﬂuence the type and strength of adhe-
sion with the ECM, integrin interactions with ECM
components can transduce signals that broadly inﬂuence
cellular attributes and behavior, including cell shape, stress
ﬁber formation, and cell motility. Thus, throughout EMT,
the integrins are involved in a variety of inside-out and
outside-in signaling events that respond to and direct
phenotypic changes.83 Two major mediators of the outside-inajp.amjpathol.org - The American Journal of Pathology
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focal adhesion kinase and integrin-linked kinase.83,86 Integrin
clustering induces activation of focal adhesion kinase, which
inﬂuences cellular proliferation, survival, and motility. Focal
adhesion kinase is expressed at higher levels in invasive tumors
than benign or preneoplastic tissue, where it is thought to play
a broad role in mediating morphogenesis and position-
dependent survival during gland formation and stem cell
maintenance.83,87 Engagement of theECMby integrins leads to
rapid and dynamic activation of integrin-linked kinase, which
has broad inﬂuences on transcriptional programs that inﬂuence
EMT, including transcriptional down-regulation of E-cadherin
and the up-regulation of mesenchymal markers, such as
vimentin.86 Loss of E-cadherin results in furthering mesen-
chymal reprogramming by altering the distribution of b-catenin
to the cytoplasm and nucleus to activate the Wnt targets.
Finally, integrins have profound inﬂuences on the composition
of the ECM through dynamic interactions and regulation of
proteases that refashion the ECM and, therefore, participate in
the constant remodeling of the tumor stroma.83,88
Although EMT has been heavily studied during the past few
years, there still remains controversy among pathologists
about its relevance to cancer. Much of this controversy centers
on how rigidly EMT should be deﬁned.76,77,79 Recent efforts
to circumscribe these concepts led to the deﬁning of three
different types of EMT (types I to III).77 Type I is associated
with embryonic development and organ formation and does
not involve ﬁbrosis or invasive attributes. Type I EMT
generates cells that maintain the plasticity necessary to
undergo the kinetically coordinated rounds of EMT and
mesenchymal-epithelial transition necessary for tissue forma-
tion and organ development. Type II EMT is associated with
wound healing, tissue regeneration, and organ ﬁbrosis, linked
to a self-limited inﬂammatory process. Type II EMT can lead
to pathological ﬁbrosis if inﬂammation persists. Type III is the
type of EMT seen in malignant epithelial cells through altered
genetic and epigenetic regulation. The entry and extent of
neoplastic cell participation in EMT is heterogeneous.77 A
central feature of the EMT-like changes seen in cancer is the
high degree of variability and plasticity. Type III EMT is not,
in the strictest sense, a completed transdifferentiation, as is
thought to occur in organ ﬁbrosis.53,77 Perhaps it is best to
think of EMT in the context of cancer as a dedifferentiated
process, or state, that is variable and highly plastic, rather than
a well-deﬁned terminal event.
A variety of genetic and epigenetic programs, driven by
a diverse array of pleiotropic transcription factors and
transcriptional regulators, control the phenotypic transition
during EMT.76,80 These include transcriptional regulators
that have been well established as EMT transcription
factors, including ZEB1,89 TWIST1,90 SNAI1 (snail),91
E47,92 and SNAI2 (slug).93 In addition to these DNA
binding proteins, multiple co-activators and corepressors
play major roles in the epigenetic regulation of EMT,
including the histone demethylase, LSD1,94 the histone
methyl-transferase, G9a,95 the histone acetyl-transferase,The American Journal of Pathology - ajp.amjpathol.orgp300,96,97 the polycomb components, Bmi190 and SUZ12,98
and NADH-regulated transcriptional corepressor C-terminal
binding protein 1/2.99e101
An unexpected characteristic associated with EMT is the
acquisition of stem cellelike traits that confer properties
of enhanced self-renewal to carcinoma cells undergoing
EMT.76,80 This occurs because there is a signiﬁcant overlap
between the regulatory networks that control EMT and those
pathways that are important for self-renewal. EMT tran-
scription factors also repress pathways that inhibit or suppress
the acquisition of stem cell traits.76,80 For example, ZEB1
inhibits miR-200, a microRNA family that represses stem cell
traits. In addition, multiple self-renewal pathways associated
with promoting stemness, such as Wnt/B-catenin signaling,
also function to stabilize EMT transcription factors, such as
SNAI1.102 The concept of cancer stem cells still remains
controversial,103 as previously stated for EMT.Aperhapsmore
palatable conceptual way to think about stem cellelike cancer
cells is to consider or deﬁne them as a highly plastic dediffer-
entiated state possessing a threshold level of stem cellelike
traits, instead of a deﬁned discrete cellular population.76,104
The Tumor Microenvironment: Dynamic
Interfaces for Cross Talk in the Extracellular
Space
Throughout this review, we have emphasized the role played
by various cellular components in the tumor stroma.
However, the extracellular space represents a complicated
and dynamic mix of growth factors, cytokines, chemokines,
and metabolic intermediates that are secreted, shed, or spilled
into the extracellular space in paracrine and autocrine
patterns that actively induce migration, differentiation, and
proliferation across each cellular component in the healing
wound or reactive tumor stroma. The levels and diversity of
the signaling components are dependent on the composition
of cells and the composition of the secreted and deposited
connective tissue, which continue to evolve in response to the
protease secretion by tumor and stromal cells. This remod-
eling changes the mechanical properties of the stroma and
can have profound inﬂuence on the latency of a variety of
growth factors that depend on interaction with distinct
components of the extracellular connective tissue to increase
or decrease the potency of ligand-receptor interactions. Thus,
the stromal interface with the tumor represents a highly
dynamic and pleiotropic space where molecular information
undergoes continuous exchange between epithelia, macro-
phages, myoﬁbroblasts, endothelial cells, and pericytes
during tumor growth and progression.
Breast Cancer, Wound Healing, and the
Postpartum Breast
Reproductive history has long been known to have a signiﬁ-
cant impact on breast cancer incidence and outcome.105e1071059
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Figure 1 Schematic diagram of the diverse cellular reprogramming that occurs during wound healing responses in the tumor stroma. Cellular processes are
italicized. Indicated are reversible transitions between 1) epithelial cells and mesenchymal phenotypes, 2) M1 macrophages and M2 macrophages, 3)
ﬁbroblasts and myoﬁbroblasts, 4) endothelial cells and myoﬁbroblasts, and 5) pericytes and myoﬁbroblasts. CCL, chemokine C-C motif ligand; FGF, ﬁbroblast
growth factor.
Byun and GardnerEarly menarche, low parity, and older age at ﬁrst pregnancy
have all been associated with increased breast cancer
risk.105e107 These observations have been traditionally
interpreted to indicate that a woman’s cumulative lifetime
exposure to estrogen and, therefore, lifetime number of
ovulatory cycles was a major positive determinant of
estrogen receptorepositive breast cancer, thereby explaining
the protection provided by pregnancy.105 However, women
with pregnancy-associated breast cancer have a higher
mortality than patients without pregnancy-associated breast
cancer.108 Moreover, in women diagnosed with estrogen
receptorenegative or triple-negative breast cancers (tumors
negative for estrogen receptor, progesterone receptor, and the
human EGF receptor 2), the reverse is true. Nulliparity is
protective, whereas high parity is associated with increased
risk and mortality.106 This association was particularly strong
in women of African heritage.109 The apparent paradox is
readily explained if one considers that, after lactation, the
involuting postpartum breast must undergo a massive wound
healing response.110e112 The involution of lactating mam-
mary epithelium involves cycles of ﬁbrin and ﬁbronectin
deposition and degradation, active turnover of the ECM by1060released MMPs, and active recruitment of inﬂammatory
components that amplify the wound healing response,
thereby providing a microenvironment that promotes tumor
growth and invasion.110,111 Thus, high parity may increase
the risk of triple-negative breast cancers secondary to
increased production and exposure of mammary epithelia to
the wound healing response after involution of the lactating
breast. Interestingly, several studies have found that pro-
longed breastfeeding is protective against triple-negative
breast cancers.109 The reason remains obscure, but some
investigators have conjectured that it may be the result of
a more tapered wound healing response and inﬂammation
with gradual weaning.113 However, recent studies by Sotgia
et al114 might provide an additional and alternative inter-
pretation. By using a mouse model of Cav-3edeleted mice,
which undergoes pronounced precocious lactation, they were
able to show that a lactogenic environment was protective
against tumor formation.114 How and why this occurs and
whether the prodifferentiation environment of the lactating
breast reduces the size of the breast epithelial progenitor
population at risk for transformation will be an important
question to address in the future.ajp.amjpathol.org - The American Journal of Pathology
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Plasticity in the Healing Wound and Tumor
Stroma
During the wound healing process and the evolution of the
reactive tumor stroma, each of the cellular constituents
responds to speciﬁc environmental clues to undergo
signiﬁcant stable, yet reversible, acquisition or loss of
speciﬁc cellular features that can be inherited by subsequent
cellular generations in the absence of alterations in DNA
sequence. Similarly, epigenetic changes represent poten-
tially reversible covalent changes to chromatin, through
DNA methylation, histone acetylation, methylation, phos-
phorylation, and ubiquitylation, that are highly responsive to
environmental inﬂuences and can be stably inherited by
subsequent generations in the absence of changes to DNA
sequence.115 These parallels indicate that epigenetic regu-
lation is likely to be one of the most important modes of
cellular phenotypic control during the wound healing
response in cancer. However, despite the general role,
epigenetic regulation is likely to play throughout wound
healing and tumor stromal expansion; little is known about
how cellular identity and the acquisition of epithelial and
mesenchymal traits are controlled at the level of chromatin
accessibility.115 A recent study provided one of the ﬁrst
assessments of epigenetic reprogramming on a genome
scale. This was accomplished using non-transformed
AML12 hepatocyte cells to proﬁle large-scale epigenetic
changes after TGF-b stimulation.116 Although DNA meth-
ylation appears unchanged, there was a global reduction in
histone H3 lysine 9 dimethylation, a known heterochro-
matin epigenetic mark, combined with an increase in histone
H3 lysine 4 trimethylation, a known mark of active
euchromatin, and an increase in histone H3 lysine 36 tri-
methylation, a mark of actively transcribing genes.116
Surprisingly, most of these changes were located in large
organized heterchromatin K9 modiﬁcation domains that are
normally situated at the periphery of the nucleus in associ-
ation with the nuclear lamina.117 Exposure to TGF-b was
associated with decondensation of the peripheral hetero-
chromatin in coordination with the histone changes.
Notably, these changes were dependent on shifts in binding
of the histone demethylase LSD1, implying a signiﬁcant
role for LSD1 in large-scale changes in chromatin during
cellular reprogramming. Future genome-scale studies of this
nature will be needed to proﬁle the role of different epige-
netic regulators in cellular reprogramming events, such as
EMT, and how their activity may be modiﬁed by the
microenvironment.
This is particularly relevant given the growing consensus
that many metabolic elements in the microenvironment may
exert profound inﬂuences on epigenetic reprogramming. In
fact, several normal products of carbohydratemetabolism have
the potential to have signiﬁcant effects on the epigenome,
including well-known metabolites, such as acetyl-CoA, whichThe American Journal of Pathology - ajp.amjpathol.orgcould inﬂuence the level of histone acetylation through
histone acetyl-transferases, such as p300.115,118 NADþ, in
combination with its reduced form, NADH, can have diverse
inﬂuences on histone acetylation through the Sirtuin family
of class III histone deacetylases and the NADH-binding
class of dimeric C-terminal binding protein corepressors
capable of recruiting class III histone deacetylases, histone
methyl-transferases, histone demethylases, and DNA
methyl-transferases.99e101 a-Ketoglutarate is a rapidly
oxidized metabolite in the tricarboxylic acid cycle and is
a substrate for both Jumonji C domain histone demethylases
and the 10 to 11 translocation protein methylcytosine
oxidases that play a role in histone demethylation and DNA
demethylation, respectively.115,119 Together, these metabo-
lites and their epigenetic regulation represent a metabolic
transduction cascade that can link metabolic parameters of
both the tumor and microenvironment to epigenetic events
important for cellular reprogramming in both wound healing
and cancer.Concluding Remarks
After nearly a century of research in the role of the micro-
environment in wound healing and the formation of tumor
stroma, the focus is shifting to understanding function and
control at the cellular level. The tumor microenvironment is
not just a stew of growth factors, cytokines, and extracel-
lular enzymes that shape the ECM. Instead, it is an active
and bustling harbor of many cells in dynamic communica-
tion with each other and undergoing shifts and changes in
cellular identity (Figure 1). The newest frontier will be to
deﬁne how the epigenome is shaped and sculpted within
each cell type, during each cellular reprogramming event,
and how the changing epigenomes within the tumor and
stroma can act in synergy during tumor progression.References
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